Combat antimicrobial resistant bacteria by reinvigorating existing antibiotics

About Medusa

We are translating a novel discovery out of academia and into the clinic

Medusa Pharmaceuticals is an Imperial College London spin out, based on a serendipitous discovery made in Dr Peter Sarkies' laboratory.

We set up the Company to bring this unique discovery to patients who need it, to treat antimicrobial resistant infections and save lives all around the world.

September 2021: Selected onto the Accelerate@Babraham 2021/22 programme, giving us mentors, non-dilutive funding and lab space at the Babraham Research Campus, where the Company is now based.
March 2022: Selected onto the BIA Pulse programme at the Crick Institute, London

Dr Peter Sarkies

Undergraduate/Masters in Biochemistry - University of Oxford

PhD (Epigenetics) - University of Cambridge

10 years in academia - Junior Research Fellow at University of Cambridge, Group Leader at Imperial College London, Associate Professor at University of Oxford

Dr James Duboff

Undergraduate/Masters in Biochemistry - University of Oxford

PhD (Microbial Genetics) - University of Cambridge

10 years in industry - R&D Scientist at GlaxoSmithKline, R&D Manager at Procter & Gamble, Business Development Director at Eagle Genomics, Strategic Partnerships Director at Genomics England

Medusa Pharmaceuticals is reinvigorating existing antibiotics by repurposing drugs in combination

About Medusa

We are translating a novel discovery out of academia and into the clinic

Dr Peter Sarkies

Dr James Duboff